- Home
- ANAB vs PDM Comparison
ANAB vs PDM Comparison
Compare ANAB & PDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- PDM
- Stock Information
- Founded
- ANAB 2005
- PDM 1997
- Country
- ANAB United States
- PDM United States
- Employees
- ANAB N/A
- PDM N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- PDM Building operators
- Sector
- ANAB Health Care
- PDM Real Estate
- Exchange
- ANAB Nasdaq
- PDM Nasdaq
- Market Cap
- ANAB 1.0B
- PDM 1.1B
- IPO Year
- ANAB 2017
- PDM N/A
- Fundamental
- Price
- ANAB $38.47
- PDM $8.28
- Analyst Decision
- ANAB Buy
- PDM Buy
- Analyst Count
- ANAB 12
- PDM 5
- Target Price
- ANAB $63.30
- PDM $9.40
- AVG Volume (30 Days)
- ANAB 364.4K
- PDM 851.8K
- Earning Date
- ANAB 11-04-2025
- PDM 10-27-2025
- Dividend Yield
- ANAB N/A
- PDM 3.02%
- EPS Growth
- ANAB N/A
- PDM N/A
- EPS
- ANAB N/A
- PDM N/A
- Revenue
- ANAB $169,467,000.00
- PDM $565,372,000.00
- Revenue This Year
- ANAB $37.52
- PDM N/A
- Revenue Next Year
- ANAB N/A
- PDM N/A
- P/E Ratio
- ANAB N/A
- PDM N/A
- Revenue Growth
- ANAB 196.42
- PDM N/A
- 52 Week Low
- ANAB $12.21
- PDM $5.46
- 52 Week High
- ANAB $40.96
- PDM $10.72
- Technical
- Relative Strength Index (RSI)
- ANAB 72.78
- PDM 48.65
- Support Level
- ANAB $34.22
- PDM $7.97
- Resistance Level
- ANAB $37.08
- PDM $8.90
- Average True Range (ATR)
- ANAB 2.03
- PDM 0.23
- MACD
- ANAB -0.18
- PDM -0.01
- Stochastic Oscillator
- ANAB 68.07
- PDM 40.52
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About PDM Piedmont Office Realty Trust Inc.
Piedmont Realty Trust Inc is a fully integrated, self-managed real estate investment company focused on delivering an exceptional office environment. As an owner, manager, developer and operator of 16 MM SF of Class A properties across major U.S. Sunbelt markets, Piedmont Realty Trust is known for its hospitality-driven approach and commitment to transforming buildings into Piedmont PLACEs that enhance each client's workplace experience.